RHY
Asset Logo

Rhythm Biosciences Limited

πŸ‡¦πŸ‡Ί ASX

🩺 HEALTH CARE

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

-7.00%
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

11
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Rhythm Biosciences Ltd. engages in the research, development, and commercialization of medical diagnostics technologies. The firm is engaged in delivering simple, affordable blood tests for accurate and early detection of cancers. The company is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives. The firm has developed ColoSTAT, a blood test for the detection of Colorectal Cancer (CRC). If diagnosed early, colorectal cancer is curable. The ColoSTAT Test-Kit measures five specific protein biomarkers that indicate the likelihood of CRC. The test is an alternative for individuals who are unable or unwilling to participate in current screening programs. The company is being updated to meet the IVDR (In vitro diagnostic medical devices regulation) regulatory standards. The company is focused on working with likeminded global partners to achieve commercialization and distribution of these simple solutions.

πŸ“ˆ Performance

Price History

-59.39%

1M

1Y

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.08

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in RHY

11

πŸ“Š Total Capital Earnings

$18K

πŸ”ƒ Average investment frequency

28 weeks

πŸ’΅ Average investment amount

$1,615

⏰ Last time a customer invested in RHY

12 days
RHY investor breakdown
πŸ’΅ Income of investors

More than 200k

7%

150k - 200k

29%

100k - 150k

29%

50k - 100k

21%

Less than 50k

14%
πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

91%
πŸ™‹ Legal gender of investors

Female

55%

Male

45%

Pearlers who invest in RHY also invest in...

Rhythm Biosciences Limited

RHYN

Rhythm Biosciences Ltd. engages in the research, development, and commercialization of medical diagnostics technologies. The firm is engaged in the development and commercialization of Australian medical diagnostics technology for sale in domestic and international markets. The Company’s ColoSTAT a blood-base cancer test, designed for the early detection of colorectal cancer, has been developed initially as an alternative screening test for individuals unable to or unwilling to use available screening modalities. ColoSTAT is indicated to screen adults, aged 40 to 85, at average risk for developing Colorectal Cancer (CRC). The test-kit measures five specific biomarkers in the blood that either increase or decrease in quantity when CRC tumors are present.

🩺 HEALTH CARE

Find Out More

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

3.62%

πŸ“Š Share price

$102.10 AUD

πŸ‡¦πŸ‡Ί AUSTRALIA

⛳️ DIVERSIFIED

🧱 MATERIALS

πŸ’Έ FINANCIALS

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

3.79%

πŸ“Š Share price

$68.90 AUD

🌏 GLOBAL

⛳️ DIVERSIFIED

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

14.02%

πŸ“Š Share price

$140.20 AUD

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

🌏 GLOBAL

πŸ€– TECHNOLOGY

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

πŸ™Œ Performance (5Yr p.a)

27.66%

πŸ“Š Share price

$50.95 AUD

πŸ‡ΊπŸ‡Έ UNITED STATES

πŸ“ˆ HIGH PRICE GROWTH

πŸ€– TECHNOLOGY

Want more shares? Try these...

πŸ“Š Share price

$0.04 AUD

Ridley Corp. Ltd. engages in the production and market of stock feed and animal feed supplements. The company is headquartered in Melbourne, Victoria. The firm operates through two segments: Packaged Feeds and Ingredients and Bulk Stockfeeds. The Packaged Feeds and Ingredients segment comprises animal nutrition feed and ingredient solutions delivered in packaged form, ranging from one ton down to three kilogram bags. The company also includes the Aquafeed Business Unit. The Bulk Stockfeeds segment includes animal nutrition stockfeed solutions delivered in bulk. Its specialist areas include Aqua Feeds, Bulk Ruminant Stockfeeds, Bulk Monogastric Stockfeeds, Animal Proteins & Oils, Commodities, NovaqPro, and Primo Aquaculture. The company manufactures and supplies a complete range of prawn/shrimp feeds and fish feeds for species, including Monodon, Vannamei, Banana, and Stylirostris prawns. The company is also a provider of dairy feed, cattle feed, and sheep feed. The company provides bulk stockfeed for monogastric animals, including layers, broilers, pigs, and ducks.

πŸ™Œ Performance (5Yr p.a)

32.04%

πŸ“Š Share price

$2.68 AUD

πŸ“ˆ HIGH PRICE GROWTH

πŸ” FOOD PRODUCTS

Red Hawk Mining Ltd. engages in the development of mineral deposits. The company is headquartered in Perth, Western Australia. The company went IPO on 2002-02-20. The firm is focused on developing its 100%-owned Blacksmith Iron Ore Project in the Pilbara region of Western Australia. The Blacksmith Project is located approximately 70km north-west of Tom Price and consists of mining lease M47/1451, which covers approximately 112 square kilometers (km2). The Blacksmith Project comprises seven shallow deposits: Ajax, Badger, Blackjack, Champion, Delta, Eagle and Paragon. In addition to the Blacksmith Project, the Company holds retention license R47/21 for the Anvil Project. Its Canegrass Project is located approximately 60 km south-east of Mt Magnet in the Murchison region of Western Australia. The tenement package comprises six granted exploration licenses, which are being explored for battery minerals, particularly vanadium and titanium.

πŸ™Œ Performance (5Yr p.a)

226.92%

πŸ“Š Share price

$0.80 AUD

⛏️ MINING

Resonance Health Ltd. operates as a healthcare company, which involves in the development and commercialization of technologies and services for the quantitative analysis of radiological images in a regulated and quality controlled environment. The company is headquartered in Perth, Western Australia. Its portfolio includes Core Lab and artificial intelligence (AI)-powered products to partner with clinicians and radiologists for diagnosis, and management of patients. Its core SaMD product is FerriScan, a non-invasive liver analysis technology used for the assessment of iron in the liver. Its other SaMDs include Cardiac T2, for the assessment of iron in the heart, and HepaFat-Scan for the assessment of fat in and around the liver. The company also has several AI-assisted SaMDs, including FerriSmart, HepaFat-AI, and LiverSmart. The company operates as the Clinical Trial Research Organisation (CRO) and local sponsor for a major global pharma company's clinical trial in Australia of a new drug compound.

πŸ™Œ Performance (5Yr p.a)

-15.75%

πŸ“Š Share price

$0.05 AUD

🩺 HEALTH CARE

Compare
Add to watchlist